



I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for

Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Floral 27, 2004

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

John K. Jackson et al.

Application No.

10/721.835

Filed

November 25, 2003

For

POLYMERIC SYSTEMS FOR DRUG DELIVERY

AND USES THEREOF

Docket No.

: 920041.416C1

Date

: April 27, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/181,582, filed October 28, 1998. The references listed on the attached forms PTO-1449 were submitted to and/or cited by the Office in this prior application and, therefore, are not required to be provided in the present application. If the Examiner wishes copies will be provided upon request.

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jeffrey C. Pepe, Ph.D.

Registration No. 46,985

JCP:ljt

Enclosures:

Postcard Transmittal Form Form PTO-1449 (4 Sheets)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\476829

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY, DOCKET NO. AP 920041.416C1 10

APPLICATION NO. 10/721,835

APPLICANTS

John K. Jackson et al.

FILING DATE

GROUP ART UNIT

November 25, 2003

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,438,253	03/20/84	Casey et al.	528	86	
	AB	4,452,973	06/05/84	Casey et al.	528	354	
	AC	4,526,938	07/02/85	Churchill et al.	525	415	
	AD	4,716,203	12/29/87	Casey et al.	525	408	
•	AE	4,826,945	05/02/89	Cohn et al.	528	76	
•	AF	4,882,168	11/21/89	Casey et al.	424	468	
	AG	4,938,763	07/03/90	Dunn et al.	604	891.1	
	AH	4,942,035	07/17/90	Churchill et al.	424	423	
	AI	5,167,649	12/01/92	Zook	604	307	
	AJ	5,278,201	01/11/94	Dunn et al.	523	113	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSI	LATION
		DOCUMENT NUMBER	DATE	COUNTRY	YES	NO
4	AK	CA 2,138,474	06/20/96	Canada		
A	AL	EP 241178 A1	10/14/87	EPO		
*	AM	EP 537559 A1	04/21/93	EPO		
+	AN	EP 539741 A1	05/05/93	EPO		
4	AO	EP 737703 A2	10/16/96	EPO		


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

X	AP	Bei et al., "Polycaprolactone-Poly (Ethylene Glycol) Block Copolymer III Drug Release Behavior," <i>Chinese J. of Polymer Sci. 13</i> (2): 154-161, 1995.
*	AQ	Cerrai et al., "Block copolymers of L-lactide and poly(ethylene glycol) for biomedical applications," <i>Journal Of Materials Science: Materials In Medicine 5</i> : 308-313, 1994.
4	AR	Cohn and Younes, "Biodegradable PEO/PLA block copolymers," J. of Biomed. Mat. Res., Vol. 22, 993-1009 (1988)

EXAMINER

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



									Sheet 2	_ OI <u>_4</u>
FORM PTO-1449					ATTY, DOCKET NO. APPLICATION NO.					
(REV.7-80)		PATE	ENT AND TRADEM	ARK OFFICE	920041.416C1 10/721,835					
1					APPLICANTS					
INFO	ORM.	ATION DISCLOSUI (Use several sheets if nece		ENT	John K. Jackson et al.					
		(Use several sheets if nece	essary)		FILING DATE	GROUP ART UNIT				
					November 25, 2003					
	<u> </u>		U.S.	PATENT	DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ss	SUBCLASS	FILING IF APPRO	
	ВА	5,607,686	03/04/97	Т	otakura et al.	42	4	426		
	вв	5,626,863	05/06/97]	Hubbell et al.	42	4	426		
•	вс	5,667,809	09/16/97	-	Γrevino et al.	42	4	501		
	BD	5,702,717	12/30/97		Cha et al.	42	4	425		
•	BE	5,944,341	11/30/99		Hunter et al.	51	4	210		
			FOREI	GN PATE	NT DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY				TRANS	
•	BF								163	NO
	Br									
		OTHE	R PRIOR A	RT (Including	g Author, Title, Date, Pertinent Pa	ges, Etc.,)			****
	BG	I I			oly(Ethylene Oxide) Di					
*	Nonisothermal Crystallization and Melting Behavior," J. of Appl. Polym. Sci.				lym. Sci.,	1793-1	804			
`		(1997)							1/ 1	
#	ВН		Hu and Liu, "Effect of soft segment on degradation kinetics in polyethylene glycol/poly(L-							y(L-
	lactide) block copolymers," <i>Polymer Bulletin 30</i> : 669-676, 1993. Jackson, J.K. et al., "A polymer-based drug delivery system for the antineoplastic ag					•				
K	ві									
					," British Journal of Co					
	BJ		Kimura et al., "Preparation of block copoly(ester-ether) comprising poly(L-lactide) and							
ギ		* * * * *	poly(oxypropylene) and degradation of its fibre in vitro and in vivo," Polymer 30: 1342-							
•	1349, 1989.									
Вк Lyatskaya and Birshtein, "Tribock Copolymers: the Role of Interfacial Tensio					al Tension	l				
Coefficients at Two Interfaces," <i>Polymer</i> , Vol. 36, No. 5, 975-980 (1995)										
~	BL	Martini et al	"The Bioac	lhesive Pro	perties of a Triblock C	Conoly	mer e	of ε-Capro	lacton	e and
AT					aceutics, Vol. 113, 223					
					Gelation of Triblock (ne Oxid	de
	ВМ				Aqueous Solution," J . (
*		90(13): 1961	-	-	iqueous boildin, J. (J.10111.	JUC.	. u. uuuy	i ulis.	
EXAMINE	ER	1 70(13). 1701	*>00, 1>>T	•	DATE CONSIDERED					
27.17.11.11										
* EXAMIN	ER:	Initial if reference consider	ed, whether or not	criteria is in co	onformance with MPEP 609. Drav	w line thre	ough ci	itation if not in		


conformance and not considered. Include copy of this form with next communication to applicant(s).

A Notion File

								Sheet 3	01 4		
FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.		APPLICATION NO.				
(REV.7-80)		PATE	NT AND TRADEM	IARK OFFICE	920041.416C1 10/721,835						
					APPLICANTS						
INFO)RM	ATION DISCLOSU	RE STATEM	ENT	John K. Jackson et al.						
		(Use several sheets if nece	ssary)		FILING DATE	GRO	UP ART UNIT				
					November 25, 2003						
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING I			
_	СА										
			FOREI	GN PATE	NT DOCUMENTS						
•		DOCUMENT NUMBER	DATE		COUNTRY			TRANSL. YES	NO NO		
	СВ										
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pag	ges, Etc.)					
	00				ck Copolymers II. Morr		Study of P	oly/ethy	lene		
	CC				Copolymers," <i>Polymer</i> .						
K-		(1992)	е-саргогасто	ile) Block (Copolymers, Tolymer 3	7., VUI.24,		71-1200			
	CD	Pechar et al	"Riodegrad	able Drug (Carriers Based on Poly(ethylene	glycol) Blo	ck			
K	CD		_	_	hys 198:1009-1020 (199	•	6-7				
	O.P.				pheres from amphiphil		and multi	block			
163	CE	copolymers: l	copolymers: Investigation of their drug encapsulation and release characteristics," Journal								
×		of Controlled	_								
	CF	Peracchia et a	al "PEG-C	oated Nanc	spheres from Amphiph	ilic Diblo	ck and Mu	ltiblock			
X		i i	,		Drug Encapsulation and						
7		Controlled Re	_		•						
	Ramaswamy M et al "Human Plasma Distribution of Free Paclitaxel and Paclitaxe						litaxel				
1	CG		-		rs," Journal of Pharma)_		
*		464, April 1997.									
				tic acid: Po	olyethylene glycol block	k copolym	ners. The i	nfluence	e of		
×	СН	•	Shah et al., "Poly-DL-lactic acid: Polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-DL-lactic acid," <i>Journal of Biomaterials</i>								
₹.		1 4 7 7	Science, Polymer Edition 5(5): 421-431, 1994.								
						Hook Can	olymor I	Synthog	,ic		
*	CI				Poly(ethylene glycol) Bers for Adv. Tech., Vol.4			Symmes	512		
					nt of a Polymeric Surgic			n for			
7	CJ			•	3(3): 368-375, 1996.						
	CK	Youxin et al	, "In-Vitro I	Degradation	n and Bovine Serum Al	bumin Re	lease of th	e ABA			
				_	Poly(L(+)Lactic Acid),				o-		
K					o Central Polyoxyethyl						
·		Release 32:12			, , , , , , , , , , , , , , , , , , ,		. ,		ŀ		
EXAMINE	R				DATE CONSIDERED						
* EXAMIN					onformance with MPEP 609. Draw		citation if not in				
conformance and not considered. Include copy of this form with next communication to applicant(s).											

Not in fib

•										Sneet 4	1 01 4	
FORM PTO-1449)	U.S. DEPARTMENT OF COMMERCE				ATTY, DOCKET NO.		APPI.	ICATION NO.			
(REV.7-80)			PATE	INT AND TRADEM	IARK OFFICE	920041.416C1 10/721,835						
						APPLICANTS						
INFO	ORM.	ATI	ON DISCLOSUE	RE STATEM	ENT	John K. Jackson et al						
		(Use several sheets if nece	essary)		FILING DATE GROUP ART UNIT						
						November 25, 2003						
				U.S.	PATENT	DOCUMENTS						
*EXAMINER INITIAL	I I DOLIMENI NUMBER I DATE I					NAME	CLA	ASS	SUBCLASS		G DATE OPRIATE	
<u> </u>	DA											
				FOREI	GN PATE	NT DOCUMENTS						
		Τ_	OCUMENT NUMBER	DATE		COLINTRY				TRANS	LATION	
·		יט	OCUMENT NUMBER	DATE		COUNTRY				YES	NO	
	DB											
			OTHE	R PRIOR A	RT (Including	g Author, Title, Date, Pertinent Pa	ges, Etc	.)				
· Pł	DC					egradable Polymeric Pa				Taxo	l: An	
+	DD		Zhang, X. et a	In Vitro and In Vivo Study," Intl. J. of Pharm., Vol. 137, 199-208 (1996) Zhang, X. et al., "Anti-tumor efficacy and biodistribution intravenous polymeric micellar paclitaxel," Anti-Cancer Drugs 8: 696-701, 1997.								
	D.F.		7hu et al. ""S	Suman Miana	aanaulaa' ((CMC) I Dropagation of	nd Ch	20500	torization	of Stor		
	DE			•	•	(SMC). I. Preparation a						
+				•		tide (PLA) Copolymers 7, 2151-2159 (1989)	, 50	urna	i oj Potym	er scie	nce:	
	DF		1	-		zation, and Properties o	_					
*			Poly(ethylene Polymer Scien	• , \		ymers: A Potential Dru	g Car	Tier,	' Journal d	of Appi	ied	
	DG											
	DH											
	D.						-					
	DI											
	DJ									9		
								= .				
	DK											
	DL											
EXAMINE	R					DATE CONSIDERED						
* EXAMIN						onformance with MPEP 609. Draw		rough c	itation if not in			
		confo	rmance and not consider	aerea. Include co	py of this form	with next communication to applic	cant(s).					



OPE VOIGE

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/721,835
Filing Date	November 25, 2003
First Named Inventor	John K. Jackson
Art Unit	
Examiner Name	
Attorney Docket No.	920041.416C1

F	NCLOSURES (check all that app	n(v)					
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement; Form PTO-1449 Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):					
Remarks	I						
SIGNATU	RE OF APPLICANT, ATTORNEY,	OR AGENT					
Individual Name Jeffrey C. Pe Reg. No. 46							
SignatureJ/	hery Ch						
Date April 27, 200	40 1						
I hereby certify that this corresponding with the United States Postal Se addressed to: Commissioner for	TIFICATE OF TRANSMISSION/MA ondence is being facsimile transmit ervice with sufficient postage as firs r Patents, P.O. Box 1450, Alexand	tted to the USPTO or deposited to the USPTO					
Typed or printed name Lawrence Teague							
Signature This collection of information is required by 37 CFR 1	5. The information is regulared to obtain or retain a benefit was 15 U.S.C. 122 and 37 CER 114 Ms collection is setting.	Date: April 27, 2004					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the earnipleted application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: V476825